Press Release

A new study reveals the “oxygen sparing” effect of Sivomixx®800

Lausanne, August 25, 2021 — A new clinical study has just been published in Nutrients, revealing the “oxygen sparing effect” of Sivomixx®800 at the intestinal level, allowing a major availability to the other vital organs. The unique property of the probiotic formula contained in Sivomixx®800 opens a new promising scenario for numerous health conditions where the need for oxygen is not fully satisfied.

Ormendes SA is proud to announce the results of a clinical study conducted with its probiotic formulation Slab51 (Sivomixx®800) now published in Nutrients. Sivomixx®800 has been evaluated in a controlled trial with sixty-nine adult COVID-19 patients with a confirmed diagnosis of SARS-CoV-2 related pneumonia (1). All patients in the study required non-invasive oxygen therapy. Patients supplemented with the probiotic, in addition to the standard therapy, showed significantly higher blood oxygen levels than those on routine therapy alone while patients on standard treatment had significantly higher oxygen requirements. In addition, fewer patients in the probiotic group were transferred to the intensive care unit (2.5% in the probiotic group vs 13.8% in the control group).

This specific probiotic formulation contained in Sivomixx®800 induces an “oxygen-sparing effect” and modulates the consumption of oxygen in the gut making it available for other critical organs, i.e,. brain, heart and liver.

This study confirms previous clinical studies (2, 3) and extends the knowledge on the mechanisms by which COVID-19-infected patients have a higher chance of survival and a reduced risk of respiratory failure when supplemented with Slab51.

The unique property of the Slab51 probiotic formula opens a new promising scenario for the prevention and treatment of numerous health conditions where the need for oxygen is not fully satisfied. In this context, Slab51 could represent a safe add-on to the standard of care drugs for a wide spectrum of invalidating diseases such as chronic fatigue, neurodegenerative disorders, neonatal hypoxia and myocardial ischemia.


SivoMixx®800 is a food supplement containing different strains of lactic acid bacteria and bifidobacteria at a concentration of 800 billion CFU (Colony Forming Units) per sachet. It is not intended to treat, prevent, or cure any disease.

More information at

About Ormendes

Ormendes is a biotechnology company focused on the development and commercialization of live biotherapeutic medicines ( Sivomixx®800 is a probiotic food supplement (


  1. Ceccarelli G. et al. Oxygen Sparing Effect of Bacteriotherapy in COVID-19 Nutrients 2021, 13(8), 2898;
  2. d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020;7:389. 10.3389/fmed.2020.00389
  3. Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr. 2020;7:613928. 10.3389/fnut.2020.613928

Press contact

Florence Pryen, Managing Director
+41 (0)79 640 75 20